GC Medical Science Corporation (KOSDAQ:142280)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,930.00
+30.00 (1.03%)
At close: Aug 11, 2026

GC Medical Science Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
4,4733,6663,5811,797-3,581-21,202
Depreciation & Amortization
3,9683,9303,7863,8544,1073,831
Loss (Gain) From Sale of Assets
-15.450.34210.989.99-3.55-3.77
Loss (Gain) From Sale of Investments
-263.56-263.56428.89396.55-650.69-49.98
Provision & Write-off of Bad Debts
-20.2-89-280.78265.8608.877,210
Other Operating Activities
-1,744-812.24-2,781559.11-263.17,252
Change in Accounts Receivable
1,132-3,4913,896-1,432502.23908.72
Change in Inventory
934.31260.69-2,384626.7315,324-9,254
Change in Accounts Payable
-4,0222,760-1,8751,058-2,273-7,545
Change in Other Net Operating Assets
2,5721,233-921.56-2,894-2,891658.53
Operating Cash Flow
7,0157,1963,6614,24110,880-18,195
Operating Cash Flow Growth
678.37%96.56%-13.69%-61.02%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,768-4,720-3,216-5,632-3,426-3,598
Sale of Property, Plant & Equipment
753.05941.1824.798.81300.15124.39
Sale (Purchase) of Intangibles
-249.81-179.29-61.18-250-75.95-
Investment in Securities
---1,793-2,472740.98
Other Investing Activities
-72.75-71.84-5.15256.95-0-
Investing Cash Flow
-3,337-4,030-3,257-3,823-5,675-3,279

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-32,50012,00013,80029,940129,900
Long-Term Debt Issued
--20,000-30,000-
Total Debt Issued
41,10032,50032,00013,80059,940129,900
Short-Term Debt Repaid
--32,500-12,000-16,216-57,212-110,187
Long-Term Debt Repaid
--3,471-25,459-1,019-962.68-889.9
Total Debt Repaid
-45,577-35,971-37,459-17,235-58,175-111,077
Net Debt Issued (Repaid)
-4,477-3,471-5,459-3,4351,76518,823
Other Financing Activities
---4.96--0-0
Financing Cash Flow
-4,477-3,471-5,464-3,4351,76518,823

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
8.36--4.989.59-62.790.71
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
-790.57-305.85-5,066-3,0076,908-2,650

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,2472,476445.24-1,3917,454-21,793
Free Cash Flow Growth
-456.00%----
Free Cash Flow Margin
3.08%2.28%0.43%-1.48%6.59%-21.43%
Free Cash Flow Per Share
121.5092.8016.65-51.96353.61-1034.47
Levered Free Cash Flow
-4,081-4,440-4,684-8,25326,702-16,568
Unlevered Free Cash Flow
-2,362-2,727-2,919-6,18528,499-15,835

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
746.35659.62465.26338.74667.841,134
Cash Income Tax Paid
7.268.1121.62134.9465.83232.3
Change in Working Capital
616.78763.57-1,285-2,64110,662-15,232